Nilotinib Tartrate

酒石酸尼罗替尼

Report date: 2025/02/28 20:00:34

Base Information

Drug NameNilotinib Tartrate
Drug Alias NameNilotinib tartaric acidDanziten
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionBcr-Abl tyrosine kinase inhibitors
TargetsBcr-Abl tyrosine kinase
Therapy Area/IndicationsLeukemia, Myeloid, Chronic-PhaseLeukemia, Myeloid, Accelerated Phase
Global Approved IndicationsLeukemia, Myeloid, Chronic-PhaseLeukemia, Myeloid, Accelerated Phase
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2024/11/07
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesAzurity Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesAzurity Pharmaceuticals Inc
Inactive CompaniesN/A
Active IndicationsLeukemia, Myeloid, Chronic-PhaseLeukemia, Myeloid, Accelerated Phase
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A